Abstract
Background: Triple-Negative Breast Cancer (TNBC) requires targeted therapies to better manage and prevent metastatic mammary gland tumors. Due to the resistance problem associated with the approved drugs, researchers are now focusing on phytochemicals for the treatment of TNBC as they possess pleiotropic mode of action and fewer side effects.
Objective: To investigate the antiproliferative effect of citronellal on triple-negative breast cancer cells.
Methods: Anticancer potential of citronellal was explored by employing SRB, MTT, and NRU antiproliferative assay. Further, the effect of citronellal was observed on molecular targets (Tubulin, COX-2, and LOX-5) utilizing in vitro and in silico methods. Furthermore, the efficacy of citronellal was examined on Ehrlich Ascites Carcinoma cells. In addition, the safety profiling of it was observed at 300 and 1000 mg/kg of body weight in mice.
Results: Citronellal suppresses the growth of MDA-MB-231 cells by more than 50% in NRU assay and ~41% and 32% in SRB and MTT assay, respectively. Further, citronellal's effect was observed on molecular targets wherein it suppressed LOX-5 activity (IC50 40.63±2.27 μM) and prevented polymerization of microtubule (IC50 63.62 μM). The result was more prominent against LOX-5 as supported by molecular docking interaction studies, but a non-significant effect was observed at the transcriptional level. The efficacy of citronellal was also determined in Ehrlich Ascites Carcinoma (EAC) model, wherein it inhibited the growth of tumor cells (45.97%) at 75 mg/kg of body weight. It was non-toxic up to 1000 mg/kg of body weight in mice and did not cause significant lysis of erythrocytes.
Conclusion: These observations could provide experimental support for citronellal to be used as a chemopreventive agent for breast cancer.
Keywords: TNBC, citronellal, molecular targets, phytochemicals, Ehrlich Ascites carcinoma, MDA-MB-231.
Graphical Abstract
Current Molecular Pharmacology
Title:Suppression of Molecular Targets and Antiproliferative Effect of Citronellal on Triple-Negative Breast Cancer Cells
Volume: 14
Author(s): Kaneez Fatima and Suaib Luqman*
Affiliation:
- Bioprospection and Product Development Division, Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow 226015, Uttar Pradesh,India
Keywords: TNBC, citronellal, molecular targets, phytochemicals, Ehrlich Ascites carcinoma, MDA-MB-231.
Abstract:
Background: Triple-Negative Breast Cancer (TNBC) requires targeted therapies to better manage and prevent metastatic mammary gland tumors. Due to the resistance problem associated with the approved drugs, researchers are now focusing on phytochemicals for the treatment of TNBC as they possess pleiotropic mode of action and fewer side effects.
Objective: To investigate the antiproliferative effect of citronellal on triple-negative breast cancer cells.
Methods: Anticancer potential of citronellal was explored by employing SRB, MTT, and NRU antiproliferative assay. Further, the effect of citronellal was observed on molecular targets (Tubulin, COX-2, and LOX-5) utilizing in vitro and in silico methods. Furthermore, the efficacy of citronellal was examined on Ehrlich Ascites Carcinoma cells. In addition, the safety profiling of it was observed at 300 and 1000 mg/kg of body weight in mice.
Results: Citronellal suppresses the growth of MDA-MB-231 cells by more than 50% in NRU assay and ~41% and 32% in SRB and MTT assay, respectively. Further, citronellal's effect was observed on molecular targets wherein it suppressed LOX-5 activity (IC50 40.63±2.27 μM) and prevented polymerization of microtubule (IC50 63.62 μM). The result was more prominent against LOX-5 as supported by molecular docking interaction studies, but a non-significant effect was observed at the transcriptional level. The efficacy of citronellal was also determined in Ehrlich Ascites Carcinoma (EAC) model, wherein it inhibited the growth of tumor cells (45.97%) at 75 mg/kg of body weight. It was non-toxic up to 1000 mg/kg of body weight in mice and did not cause significant lysis of erythrocytes.
Conclusion: These observations could provide experimental support for citronellal to be used as a chemopreventive agent for breast cancer.
Export Options
About this article
Cite this article as:
Fatima Kaneez and Luqman Suaib*, Suppression of Molecular Targets and Antiproliferative Effect of Citronellal on Triple-Negative Breast Cancer Cells, Current Molecular Pharmacology 2021; 14 (6) : e301221192166 . https://dx.doi.org/10.2174/1874467214666210309120626
DOI https://dx.doi.org/10.2174/1874467214666210309120626 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era
Current Drug Metabolism Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy Evaluation of the Cytotoxicity and Apoptotic Induction in Human Liver Cell Lines Exposed to Three Food Additives
Recent Patents on Food, Nutrition & Agriculture Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology SALL4: Engine of Cell Stemness
Current Gene Therapy Role of Cyclooxygenases in Angiogenesis
Current Medicinal Chemistry Antiangiogenic Agents in the Treatment of HER2-Negative Metastatic breast Cancer: A Brief Review
Current Angiogenesis (Discontinued) Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Subcellular Analysis of the Platelet Proteome
Current Proteomics Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Genetic Abnormalities in Prostate Cancer
Current Genomics Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Current Cancer Drug Targets Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry